Efficacy stem cells in improving the symptoms of patients with lupus
Phase 2
Recruiting
- Conditions
- Systemic lupus erythematosus.Systemic lupus erythematosus (SLE)
- Registration Number
- IRCT20130812014333N182
- Lead Sponsor
- Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Class 3 or 4 resistant lupus nephritis
Parenchymal lung involvement or refractory heart involvement
Resistant vasculitis
Resistant CNS involvement
Exclusion Criteria
Other autoimmune diseases
Uncontrolled high blood pressure
Diabetes and other endocrine disorders
Cardiovascular failure
Severe renal failure and need to dialysis
Hepatic impairment
Depression
Endocarditis
Lupus pneumonia
Pregnancy and breast-feeding
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Anti-Nuclear Antibody (ANA). Timepoint: 2 to 3 days after injection every 6 to 8 weeks. Method of measurement: Taking blood from the arm area.;Antiphospholipid antibodies. Timepoint: 2 to 3 days after injection every 6 to 8 weeks. Method of measurement: In the laboratory with a blood test.;Glucose. Timepoint: 2 to 3 days after injection every 6 to 8 weeks. Method of measurement: In the laboratory with a blood test.;Triglyceride. Timepoint: 2 to 3 days after injection every 6 to 8 weeks. Method of measurement: In the laboratory with a blood test.
- Secondary Outcome Measures
Name Time Method